<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> followed by reperfusion activates numerous pathways that lead to cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>One such pathway involves the release of large quantities of the excitatory amino acid <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> into the synapse and activation of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptors </plain></SENT>
<SENT sid="2" pm="."><plain>This causes an increase in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> calcium levels ([Ca(2+)](m)) and a production of reactive oxygen species (ROS), both of which may induce the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> permeability transition (MPT) </plain></SENT>
<SENT sid="3" pm="."><plain>As a consequence, there is eventual <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> failure culminating in either apoptotic or necrotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, agents that inhibit MPT might prove useful as therapeutic interventions in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we have investigated the neuroprotective efficacy of the novel compound NIM811 </plain></SENT>
<SENT sid="6" pm="."><plain>Similar in structure of its parent compound <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, NIM811 is a potent inhibitor of the MPT </plain></SENT>
<SENT sid="7" pm="."><plain>Unlike <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, however, it is essentially void of immunosuppressive actions, allowing the role of MPT to be clarified in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury </plain></SENT>
<SENT sid="8" pm="."><plain>The results of these studies demonstrate that NIM811 provides almost 40% protection in a model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>This was associated with a nearly 10% reduction in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> reactive species formation and 34% and 38% reduction of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release in core and penumbra, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment with NIM811 also increased calcium retention capacity by approximately 20% </plain></SENT>
<SENT sid="11" pm="."><plain>Interestingly, NIM811 failed to improve <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced impairment of bioenergetics </plain></SENT>
<SENT sid="12" pm="."><plain>The neuroprotective effects of NIM811 were not due to drug-induced alterations in cerebral perfusion after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Activation of MPT appears to be an important process in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury and may be a therapeutic target </plain></SENT>
</text></document>